Kit for the Preparation of Technetium Tc 99m Sestamibi Injection
Tc 99m Sestamibi
Equivalence. Confidence. Trust. Value.
Launched in September 2008, Covidien Tc 99m Sestamibi is fully substitutable for the branded product, and delivers a high degree of diagnostic accuracy1,2. Covidien is one of the largest manufacturers of generic pharmaceuticals, with over 40 years of strong history in the radiopharmaceutical industry.
Covidien’s investment in Tc 99m Sestamibi broadens the selection of nuclear cardiology products in Covidien’s portfolio, offering our customers choice and demonstrating our commitment to provide optimum value to nuclear medicine professionals.
To view images using Covidien’s Kit for the Preparation of Technetium Tc 99m Sestamibi Injection (Tc 99m Sestamibi) , click on the attached document on the right of this page.
Important Safety Information
Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Kit for the Preparation of Technetium Tc 99m Sestamibi Injection (Tc 99m Sestamibi) has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell. In clinical studies for breast imaging, breast pain was reported in 1.7% of patients.
1. Klocke, Francis J. et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging. 2003; p. 10-11.
2. Kapur, Akhil et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med. 2002; 29: 1608-1616.